PHVS says oral drug met main goal in late-stage hereditary angioedema trial
Pharvaris said its experimental oral drug prevented swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial. Shares were up over 25% in premarket trading.
Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial. Shares of the company were up over 25% in premarket trading.